



ANZIPTR Report 2020

Australia and New Zealand Islet and Pancreas Transplant Registry data 1984-2019

This report is a compilation of data provided by Pancreas transplant units in Australia and New Zealand. The registry is funded in part by a grant from the Organ and Tissue Authority
www.anziptr.org

Contents

Sections

Contents.....	i
Sections	i
Tables	iii
Figures	vi
Summary	1
Introduction.....	1
Suggested Citation	1
ANZIPTR staff.....	1
Contact the ANZIPTR.....	2
Governance structure	2
Data release guidelines	2
Participating Centres	4
Analysis and Methods	6
Definitions	7
Glossary	1
Synopsis.....	2
Accessing report data.....	2
Chapter 1: Waiting List.....	3
Overview of waiting list activity	3
Patient waiting list flow.....	4
Distribution of active patients by state.....	5
New referrals received over time	7
Patient characteristics for those active on the list in 2019.....	8
Chapter 2: Pancreas transplant recipients.....	9
Pancreas transplant incidence	9
Patients transplanted by state	12
Demographics of new pancreas transplant recipients	13
Balance of donor and recipient characteristics in 2019.....	14
Patient survival.....	15
Pancreas survival.....	18

Prevalence of functioning pancreas transplants.....	23
Kidney transplant survival	24
Pancreas transplant operative data	28
Surgical technique	29
Chapter 3: Pancreas donors.....	32
Pancreas donor characteristics	33
Donor and recipient state/territory	36
Chapter 4: Islet cell transplants	37
Islet isolations.....	39
Islet transplant recipients.....	49
Chapter 5: Islet auto-transplants	58
Waiting list and isolation activity	59
Patient characteristics	60
Appendices.....	61
Previous ANZIPTR Reports	61
Other abstracts and publications	61

Tables

Table 1.1: Waiting list activity in Australia for the last three years.....	4
Table 1.2: Waiting list activity in New Zealand for the last three years	4
Table 1.3: Patient state of residence by Australian pancreas transplant unit for people active on the list, December 2018.....	5
Table 1.4: Patient state of residence by Australian pancreas transplant unit for people under consideration and active on the list, December 2018	6
Table 1.5: New referrals received over time by pancreas transplant unit and state of residence.....	7
Table 2.1: Pancreas transplant operations over time, by transplant hospital	11
Table 2.2: Distribution of state of residence of people receiving pancreas transplants over time	12
Table 2.3: Demographics and characteristics of pancreas transplant recipients.....	13
Table 2.4: Transplant and donor types in 2018 by country and sex.....	14
Table 2.5: Cross tabulation of recipient and donor blood groups for 2018	14
Table 2.6: Cross tabulation of recipient and donor sex for 2018	14
Table 2.7: Pancreas transplant survival censored at death, by country and era	22
Table 2.8: People alive with a functioning pancreas transplant in Australia and New Zealand by year and residence, at year's end	23
Table 2.9: Descriptive characteristics of pancreas transplant operations	28
Table 2.10: Comparison of cold ischaemic time of pancreas transplants by donor state, for Australian pancreas transplants 2018	29
Table 2.11: Immunological cross-matching of donor recipient pairs	31
Table 2.12: Infectious disease serology cross-tabulation of donor-recipient pairs	31
Table 3.1: Demographics and characteristics of pancreas transplant donors	33
Table 3.2: Distribution of state of residence of pancreas donors in Australia over time, by national pancreas transplant unit.....	34

Table 3.3: Number of pancreas transplants by donor and recipient state of residence in Australia for 2018 and all years	36
Table 4.1: Referrals for allogenic islet transplant during 2018 by state of residence and transplant centre	38
Table 4.2: Patients accepted onto a waiting list for an allogenic islet transplant during 2018 by state of residence and transplant centre.....	38
Table 4.3: Islet waiting list status over time; Westmead Hospital (NSW), St Vincent's Hospital (VIC), and Royal Adelaide Hospital (SA)	39
Table 4.4: Summary of allogenic islet cell isolation activity, for all centres in Australia.....	40
Table 4.5: Donor characteristics from allogenic islet isolations performed in Westmead Hospital (NSW).....	41
Table 4.6: Donor characteristics for allogenic islet isolations performed in St Vincent's Hospital (VIC)	43
Table 4.7: Donor characteristics for allogenic islet isolations (all centres)	45
Table 4.8: Donor characteristics for allogenic islet isolations which resulted in transplantation in 2018.....	47
Table 4.9: Cross tabulation of recipient and donor blood groups, 2002-2018, from allogenic islet transplants undertaken in Westmead Hospital (NSW)	50
Table 4.10: Cross tabulation of recipient and donor blood groups, 2002-2018, from allogenic islet transplants undertaken in St Vincent's hospital (VIC)	50
Table 4.11: Cross tabulation of recipient and donor blood groups, 2002-2018, from allogenic islet transplants undertaken in Royal Adelaide Hospital (SA)	50
Table 4.12: Cross tabulation of recipient and donor sex, 2002-2018	51
Table 4.13: Cross tabulation of recipient and donor blood groups, 2002-2018, for allogenic islet transplants undertaken in Australia.....	51
Table 4.14: Allogenic islet transplant recipients by state of residence and number of transplants received (all centres, 2018)	51
Table 4.15: Cross tabulation of allogenic islet donor and recipient state of residence in 2018	52

Table 4.16: Cross tabulation of allogenic islet donor and recipient state of residence 2002-2018	53
Table 4.17: Characteristics of allogenic islet cell transplant recipients in Australia by year of first transplant	54
Table 5.1: Patients waiting for an auto-islet transplant at the end of 2018, by transplant centre	59
Table 5.2: Auto-islet isolation/transplant activity by year	59
Table 5.3: Characteristics of auto-islet transplant recipients by year of transplant	60

Figures

Figure 1.1: Distribution of people active on the waiting list by state or country of residence, as of December 2019	5
Figure 1.2: Distribution of people active on the list by their blood group, at December 2019	8
Figure 1.3: Distribution of people active on the list by their age, at December 2019	8
Figure 2.1: Incidence of pancreas transplants over time, 1984-2019	9
Figure 2.2: Pancreas transplants over time by type, Australia and New Zealand	10
Figure 2.3: Patient survival following pancreas transplantation in Australia and New Zealand.	15
Figure 2.4: Patient survival by era of transplantation	16
Figure 2.5: Patient survival by age at transplantation	17
Figure 2.6: Pancreas transplant survival (censored at death)	18
Figure 2.7: Pancreas transplant survival (including death as transplant failure)	19
Figure 2.8: Pancreas transplant survival over time (censored at death).....	20
Figure 2.9: Pancreas transplant survival by donor BMI (censored at death)	21
Figure 2.10: Pancreas transplant survival by donor age (censored at death)	22
Figure 2.11: Kidney transplant survival for people receiving SPK transplants (censored at death).....	24
Figure 2.12: Kidney transplant survival for people receiving SPK transplants (including death as a kidney transplant failure)	25
Figure 2.13: Kidney transplant survival for SPK recipients over time (censored at death).....	26
Figure 2.14: Kidney transplant survival for SPK recipients over time (including death as a kidney transplant failure).....	27
Figure 2.15: Change in management of exocrine drainage of the pancreas over time	29
Figure 2.16: Site of donor artery anastomosis onto recipient vessel.....	30
Figure 2.17: Site of donor vein anastomosis onto recipient vessel.....	30
Figure 4.1: Allogenic islet transplant activity 2002-2018, by transplanting centre.....	49

Figure 4.2: Time from activation on a waiting list to first allogenic islet transplant	55
Figure 4.3: Time from first to second allogenic islet transplant	56
Figure 4.4: Time from second to third allogenic islet transplant	56
Figure 4.5: Duration of insulin independence from time first ceased	57

Summary

Introduction

This report is produced and edited by: Professor Angela Webster, James Hedley and Associate Professor Patrick Kelly.

Chapters 1-3 are authored by: Angela Webster, Paul Robertson, Tia Mark, James Hedley, Patrick Kelly

Chapter 4 is authored by: Patricia Anderson, Natasha Rogers, James Hedley, Angela Webster

Chapter 5 is authored by: Toby Coates, James Hedley, Angela Webster

Chapter 6 is authored by: James Hedley, Patrick Kelly, Angela Webster

We thank all contributors who have made the registry what it is and whose work has made this report possible.

Suggested Citation

Authors: *[chapter authors]*, *[chapter]* ANZIPTR report 2020; Editors Webster AC, Hedley J, Kelly PJ. Australian and New Zealand Islet and Pancreas Transplant Registry, Sydney, Australia. 2020 *[page numbers]*.

ANZIPTR staff

Prof Angela Webster	Executive Officer
Mr Paul Robertson	Transplant Co-ordinator
Mr James Hedley	Data Manager
Ms Julie McKelvey	Registry Clerk
A/Prof Patrick Kelly	Biostatistics Consultant

Contact the ANZIPTR

Inquiries or comments should be directed to ANZIPTR:

Australia and New Zealand Islet and Pancreas Transplant Unit

Westmead NSW 2145

Phone: +61 2 9845 6962

Fax: +61 2 9633 9351

Email: info@anziptr.org

Governance structure

This report is a compilation of data provided by the four current solid-organ Pancreas transplant units in Australia and New Zealand: Auckland Renal Transplant Group, New Zealand; National Pancreas Transplant Unit Monash Medical Centre, Victoria; National Pancreas Transplant Unit, Westmead Hospital, NSW; South Australian/Northern Territory Pancreas/Islet and Renal Transplant Service, Royal Adelaide Hospital, SA; and the three Islet transplanting units in Australia: Westmead Hospital (New South Wales), St. Vincent's Hospital Melbourne (Victoria), and Royal Adelaide Hospital (South Australia). The ANZIPTR registry is funded in part by a grant from the Organ and Tissue Authority.

Data release guidelines

The registry can provide de-identified data for free to Transplant Physicians, Transplant Units, and Government Departments. Release of data for academic or clinical research projects is provisional on an agreed project plan and proof of ethical oversight. The registry will not provide any personally identifiable data.

The clinical data provided contains potentially sensitive information and should be used only within agreed guidelines. If data are further published elsewhere ANZIPTR permission is necessary prior to submission for publication, and ANZIPTR should be identified as the source of the data. If data provided by ANZIPTR is the primary source of data, then a copy of publication should be provided to ANZIPTR.

Data provided by ANZIPTR should be utilised by requesting parties only, further data sharing with other parties or projects is not permitted without prior approval from ANZIPTR. The

data supplied will be in accordance with ANZIPTR data specifications. Please see www.anziptr.org for our data dictionary.

Participating Centres

Solid pancreas

Australian National Program:

Westmead Hospital

A/Prof Germaine Wong	Director of Transplant and Renal Medicine
Prof Angela Webster	Executive Director
A/Prof Natasha Rogers	Director of the Islet Cell Transplant Program
Dr Brian Nankivell	Physician
Dr Titi Chen	Physician
Dr Ankit Sharma	Physician
Prof Henry Pleass	Director of Transplant Surgery
Dr Lawrence Yuen	Surgeon
Dr Taina Lee	Surgeon
Ms Kathy Kable	Transplant Nurse Practitioner
Mr Paul Robertson	Transplant Co-ordinator

Monash Medical Centre

Prof Peter Kerr	Director of Nephrology
Prof John Kanellis	Director of Transplantation
A/Prof William Mulley	Physician
Mr Alan Saunder	Director of Surgery
Mr Roger Bell	Surgeon
Mr Ming Yii	Surgeon
Miss Nancy Suh	Surgeon
Mr Stephen Thwaites	Surgeon
Mr Michael Wu	Surgeon
Miss Sherry Salter	Surgeon
Mrs Tia Mark	Transplant Clinical Nurse Consultant

Other:

Royal Adelaide Hospital

Prof Toby Coates	Director of Transplantation
Dr Shantanu Bhattacharjya	Surgeon
Prof Randall Faull	Director of Renal Unit
A/Prof Robert Carroll	Physician
A/Prof Philip Clayton	Physician
Dr Christine Russell	Surgeon
Dr Santosh Antony-Olakkengil	Surgeon
Ms Danielle Stephenson	Nurse Unit Manager
Ms Jill Diack	Transplant Coordinator
Ms Hilary Styles	Transplant coordinator

New Zealand:

Auckland Renal Transplant Group

Dr Helen Pilmore
Dr Carl MuthuKumaraswamy

Islet Cell

Westmead Hospital

A/Prof Natasha Rogers	Director of the Islet Cell Transplant Program,
Prof Henry Pleass	Director of Transplant Surgery
Prof Wayne Hawthorne	Lead, Islet Isolation Team
A/Prof Jane Holmes-Walker	Senior Staff Specialist, Diabetes and Endocrinology
Mrs Patricia Anderson	Clinical Nurse Consultant
Ms Lindy Williams	Operations Manager Islet Isolation
Dr YiVee Chew	Scientific Officer, Islet Isolation
Dr Mojgan Nazari	Scientific Officer, Islet Isolation

St. Vincent's Hospital

To be confirmed

Royal Adelaide Hospital

Prof Toby Coates	Director of Transplantation
Mr Chris Drogemuller	Senior Scientist
Ms Svetlana Kireta	Scientist
Ms Colleen Etherton	Transplant Coordinator
Ms Toni Radford	Transplant Coordinator
Prof David Torpey	Endocrinologist
Dr Jenny Couper	Endocrinologist
Dr Anthony Roberts	Endocrinologist
Prof John Chen	Surgeon
Dr Eu Ling Neo	Surgeon
Dr Sanjeev Khurana	Surgeon
Ms Cassie Dujmovic	Nurse Consultant WCH
Dr Sharon Keripin	Pain Consultant
Dr Tim Semple	Pain consultant
Dr Tuan Vo	Pain consultant
Dr Pam Macintyre	Pain consultant
Ms Marie Dow	Pain Psychologist
Dr Richard Couper	Gastroenterologist
Dr Dan Madigan	Interventional Radiographer
Dr Ramon Pathi	Interventional Radiographer
Dr Michael Wilks	Interventional Radiographer
Dr Kenneth Chan	Interventional Radiographer

Analysis and Methods

The aim of this report is to record all pancreas transplant activity in Australia and New Zealand. Data included in this report was locked on 20th July 2020, for all people transplanted up to the end of 2019. Data for the islets waiting list, donors, and recipients was provided by each centre by 18th September 2020. Please note new data is added to the registry regularly, and corrections are made where previous data are missing or where errors are discovered.

Kaplan-Meier survival curves were used to illustrate the survival distributions, and these were generated using Stata software version 16 (StataCorp, College Station, TX USA). Transplant survival is analysed and presented both including and excluding death with a

functioning transplant. For patients receiving a second transplant, in calculating mortality, time was measured from time of first transplant.

Definitions

Pancreas transplant

A functioning pancreas transplant is defined as a recipient free of exogenous insulin dependence; thus a pancreas transplant failure is declared when either a pancreatectomy is performed, or when the recipient returns to permanent insulin therapy. Kidney transplants are defined as functioning if recipients are dialysis free. All causes of death are included in the mortality analyses.

Islet transplant

An islet transplant is the infusion of islet cells that have been isolated from a donor pancreas into a recipient with poorly controlled type 1 diabetes who has recurrent severe hypoglycaemia and hypoglycaemia unawareness. In the case of an islet auto-transplant, the recipient is also the donor. Auto-islet transplantation is the re-infusion of islet cells from isolated from the recipient's own pancreas after the pancreas has been removed. This procedure is done to eradicate the severe pain of chronic or hereditary pancreatitis, to better control blood glucose after the pancreas is removed. In this report "islet transplant" refers to islet cell infusion from a cadaveric donor only; when discussing auto-islet transplantation "auto-islet" is always specified.

A functioning islet transplant is defined as stable blood glucose levels, cessation of severe hypoglycaemia, positive blood C-Peptide levels and reduction in insulin usage. Insulin independence may or may not be achieved and is not the aim of the procedure. Insulin independence is defined as being free from insulin use for 14 or more consecutive days. Note that the definition used here is different from the international Collaborative Islet Transplant Registry (CITR, <https://citregistry.org/>), which defines insulin independence as less than 7 units of insulin per day.

Glossary

SPK	Simultaneous Kidney Pancreas Transplant
PTA	Pancreas Transplant Alone
PAK	Pancreas after Kidney Transplant
ITA	Islet Transplant Alone
PLK	Pancreas Liver Kidney
PLI	Pancreas Liver Intestine
DBD	Donor after Brain Death
DCD	Donor after Circulatory Death
CMV	Cytomegalovirus
EBV	Epstein-Barr Virus
IgG	Immunoglobulin G antibody
IEQ	Islet Equivalent Units
GMP	Good Manufacturing Procedures
TGA	Therapeutic Goods Administration (Australia)
TP-IAT	Total Pancreatectomy – Islet Auto Transplant
HbA1c	Glycosylated haemoglobin A1c
SF36	36 Item Short Form Health Survey
SD	Standard Deviation
IQR	Interquartile Range
SVHM	St. Vincent's Hospital Melbourne
SVI	St. Vincent's Institute
NSW	New South Wales
VIC	Victoria
QLD	Queensland
SA	South Australia
WA	Western Australia
TAS	Tasmania
ACT	Australian Capital Territory
NT	Northern Territory
NZ	New Zealand

Synopsis

A total of 910 solid organ pancreas transplants have been performed in Australia and New Zealand (ANZ), in 889 individuals from 1984-2019 (excluding islet transplants).

In 2019, 44 pancreas transplants were performed, by centre this was; Auckland (4); Monash (10); Westmead (27); and Adelaide (3). In 2019, 42 transplants were SPK while 2 were PAK and none were PTA.

From 2002-2019, there have been 121 Islet transplants in 65 patients (excluding auto-islets), and 7 TP-IAT procedures performed in Australia.

Accessing report data

In 2015 ANZIPTR developed its own website: www.anziptr.org which describes the registry structure and function, outlines the procedure for data requests, and provides a download area for past reports. Since 2017, a slide set of key registry data tables and plots is available for download, to complement the ANZIPTR report.

The ANZIPTR welcomes suggestions for improvement or specific analyses you would like to see in the next annual report.

Chapter 1: Waiting List

Authors: Angela Webster, Paul Robertson, Tia Mark, James Hedley, Patrick Kelly

Overview of waiting list activity

Definitions

Patients join the waiting list on the date they are referred to the transplanting centre; however, this may occur some time before their kidneys fail. Patients are therefore classified as “under consideration” until they medically require a kidney pancreas transplant. Once they require a kidney pancreas transplant they are classified as “active” on the list while they remain medically fit. The “under consideration” classification also captures people recently referred to the transplant centre, who are still undergoing assessment about their medical fitness for pancreas transplant. People referred to a transplanting centre when they are already on dialysis, become “active” on the list as soon as they are accepted as medically fit. People referred to a transplanting centre when their kidneys still function, become active once their kidney disease progresses to such a level that dialysis is planned in the near future. Once active on the waiting list, patients are transplanted in order of their waiting time, by blood group.

Patient waiting list flow

The patient waiting list activity in the last three years for Australia (Westmead and Monash Units) and New Zealand are shown in Tables 1.1 and 1.2 respectively. In Australia, although the number of transplants has increased over the last three years, the number of patients on the active waiting list has continued to increase.

Table 1.1: Waiting list activity in Australia for the last three years

Activity	Patients (n)		
	2017	2018	2019
On active list at beginning of year	51	75	47
Added to active list during the year	83	36	51
Removed from active list during year	6	6	1
Pancreas transplants to patients on waiting list ¹	48	50	40
Kidney only transplants to patients on waiting list	3	5	2
Transplants performed outside Australia/New Zealand	0	0	0
Died while active on list	2	3	6
On active waiting list at the end of year	75	47	49
Died within 12 months of removal from list	0	0	0
Under consideration but not active on list	186	203	176
Referred but declined for pancreas transplantation	57	60	63

¹ Includes one combined kidney islet transplant performed in 2017

Table 1.2: Waiting list activity in New Zealand for the last three years

Activity	Patients (n)		
	2017	2018	2019
On active list at beginning of year	3	5	2
Added to active list during the year	6	5	5
Removed from active list during year	0	2	0
Transplants to patients on waiting list	4	6	4
Kidney only transplants to patients on waiting list	0	0	0
Transplants performed outside Australia/New Zealand	0	0	0
Died while active on list	0	0	0
On active waiting list at the end of year	5	2	3
Died within 12 months of removal from list	0	0	0
Under consideration but not active on list	3	10	5
Referred but declined for pancreas transplantation	0	1	1

Distribution of active patients by state

Figure 1.1 and Table 1.3 show the state and country of residence for people active on the pancreas waiting list, by year and the pancreas transplanting centre they were referred to (Australia only).

Figure 1.1: Distribution of people active on the waiting list by state or country of residence, as of December 2019




Table 1.3: Patient state of residence by Australian pancreas transplant unit for people active on the list, December 2019

People active on the list, December 2019									
	State of residence, n (row %)								
Year	NSW	VIC	QLD	WA	SA	TAS	ACT	NT	Total
Westmead (NSW)									
2019	6 (27)	1 (5)	9 (41)	6 (27)	0 (0)	0 (0)	0 (0)	0 (0)	22
2018	12 (44)	0 (0)	11 (41)	4 (15)	0 (0)	0 (0)	0 (0)	0 (0)	27
2017	24 (51)	0 (0)	15 (32)	7 (15)	1 (2)	0 (0)	0 (0)	0 (0)	47
Monash (VIC)									
2019	1 (4)	18 (75)	0 (0)	0 (0)	1 (4)	4 (17)	0 (0)	0 (0)	24
2018	0 (0)	15 (75)	0 (0)	0 (0)	2 (10)	3 (15)	0 (0)	0 (0)	20
2017	0 (0)	20 (74)	0 (0)	0 (0)	4 (15)	3 (11)	0 (0)	0 (0)	27
Royal Adelaide (SA)									
2019	0 (0)	0 (0)	0 (0)	0 (0)	3 (100)	0 (0)	0 (0)	0 (0)	3
2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
2017	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	1

Table 1.4 shows the state of residence for people who are under consideration together with people who are active on the pancreas waiting list, by the pancreas transplanting

centre they were referred to, in Australia. For New Zealand data, there is no breakdown beyond that seen in Table 1.2.

Table 1.4: Patient state of residence by Australian pancreas transplant unit for people under consideration and active on the list, December 2019

State of residence, n (row %)									
Year	NSW	VIC	QLD	WA	SA	TAS	ACT	NT	Total
Westmead (NSW)									
2019	37 (32)	1 (<1)	33 (28)	37 (32)	7 (6)	1 (<1)	0 (0)	0 (0)	116
2018	51 (36)	1 (<1)	42 (30)	39 (28)	7 (5)	1 (<1)	0 (0)	0 (0)	141
2017	62 (40)	0 (0)	44 (28)	41 (26)	8 (5)	1 (<1)	0 (0)	0 (0)	156
Monash (VIC)									
2019	2 (2)	81 (77)	1 (<1)	0 (0)	8 (8)	12 (11)	0 (0)	1 (<1)	105
2018	4 (4)	79 (75)	1 (<1)	0 (0)	10 (10)	10 (10)	0 (0)	1 (<1)	105
2017	1 (<1)	79 (78)	1 (<1)	0 (0)	10 (10)	9 (9)	0 (0)	1 (<1)	101
Royal Adelaide (SA)									
2019	0 (0)	0 (0)	0 (0)	0 (0)	4 (100)	0 (0)	0 (0)	0 (0)	4
2018	0 (0)	0 (0)	0 (0)	0 (0)	4 (100)	0 (0)	0 (0)	0 (0)	4
2017	0 (0)	0 (0)	0 (0)	0 (0)	4 (100)	0 (0)	0 (0)	0 (0)	4

New referrals received over time

Table 1.5 shows the number of new referrals received by transplanting units in Australia and New Zealand over time, and by state of residence (for Australian units only).

Table 1.5: New referrals received over time by pancreas transplant unit and state of residence

State of residence, n (row %)									
Year	NSW	VIC	QLD	WA	SA	TAS	ACT	NT	Total
Westmead (NSW)									
2019	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1
2018	5 (36)	1 (7)	6 (43)	1 (7)	1 (7)	0 (0)	0 (0)	0 (0)	14
2017	24 (59)	0 (0)	15 (37)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	41
Monash (VIC) ¹									
2019	0 (0)	27 (90)	0 (0)	0 (0)	0 (0)	3 (10)	0 (0)	0 (0)	30
2018	3 (8)	26 (72)	1 (3)	0 (0)	2 (6)	4 (11)	0 (0)	0 (0)	36
2017	0 (0)	40 (85)	1 (2)	0 (0)	3 (6)	2 (4)	0 (0)	1 (2)	47
Royal Adelaide (SA)									
2019	0 (0)	0 (0)	0 (0)	0 (0)	3 (100)	0 (0)	0 (0)	0 (0)	3
2018	0 (0)	0 (0)	0 (0)	0 (0)	4 (100)	0 (0)	0 (0)	0 (0)	4
2017	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	2
Auckland (NZ)									
2019	-	-	-	-	-	-	-	-	2
2018	-	-	-	-	-	-	-	-	10
2017	-	-	-	-	-	-	-	-	4

¹ Excludes one multi-organ pancreas transplant for a Victorian resident performed at Austin Hospital in 2017

Patient characteristics for those active on the list in 2019

The following figures illustrate the distribution of other characteristics of those active on the waiting list in 2019, including the distribution of blood groups and patient ages.

Figure 1.2: Distribution of people active on the list by their blood group, at December 2019





Figure 1.3: Distribution of people active on the list by their age, at December 2019




Chapter 2: Pancreas transplant recipients

Authors: Angela Webster, Paul Robertson, Tia Mark, James Hedley, Patrick Kelly

Pancreas transplant incidence

A total of 910 solid organ pancreas transplants have been performed in Australia and New Zealand (ANZ) from 1984-2019. Transplants have been performed in Westmead (560), Monash (273), Auckland (66), and Royal Adelaide (7). In 2019 the Royal Adelaide Hospital recommenced pancreas transplantation in South Australia and the Northern Territory using an ATG based steroid free protocol. There have also been multi-organ transplants including pancreas at Royal Prince Alfred (1), Royal Melbourne Hospital (1), Queen Elizabeth Hospital (1), and Austin Hospital (1). Figure 2.1 shows pancreas transplants over time. The number of transplants has substantially increased in last decade compared to previous years.

Figure 2.1: Incidence of pancreas transplants over time, 1984-2019



Note: There have been four pancreas transplants performed in Australia, which were not conducted by either Westmead, Monash, or Royal Adelaide. These occurred in 1988, 1990, 2005, and 2017

In 2019, 44 people received a pancreas transplant, by centre this was; Monash (10), Westmead (27), Royal Adelaide (3), and Auckland (4). The number of transplants in 2019 decreased by 21% compared to 2018.

Not all pancreas transplant operations are undertaken with the same organs. Simultaneous pancreas-kidney transplant (SPK) is the most common operation, representing 99% of all pancreas transplants in Australia and New Zealand. From 44 transplants performed in 2018, 42 were SPK, 2 were Pancreas after kidney (PAK), and none were Pancreas transplant alone (PTA). PAK operations are done for type 1 diabetic people who either had a first kidney transplant without a pancreas (most commonly from a living donor relative) and subsequently opt for a pancreas, or for people who underwent an SPK and have good kidney transplant function, but had a pancreas transplant failure, so need a further pancreas transplant. Pancreas transplant alone (PTA) is a less common operation and occurs very rarely. Its indications include management of patients with hypoglycaemic unawareness or brittle diabetes that have failed best medical therapy. On rarer occasions, a multi-organ transplant is undertaken which includes a pancreas transplant. There was one simultaneous pancreas, liver, and kidney transplant which was performed in 2005, one liver, pancreas, and intestine transplant in 2012, one liver and pancreas transplant in 2016, and one liver, kidney, pancreas, stomach and intestine transplant in 2017. The distribution of operation types is shown in Figure 2.2, and the number of transplants by operation type is shown in Table 2.1.

Figure 2.2: Pancreas transplants over time by type, Australia and New Zealand




Table 2.1: Pancreas transplant operations over time, by transplant hospital

Hospital and transplant type, n (row %)									
Year	Westmead			Monash			Royal Adelaide	New Zealand	Total
	SPK	PAK	PTA	SPK	PAK	PTA	All	All	All
2019	26 (59)	1 (2)	0 (0)	10 (23)	0 (0)	0 (0)	3 (7)	4 (9)	44
2018	24 (43)	2 (4)	0 (0)	20 (36)	0 (0)	0 (0)	4 (7)	6 (11)	56
2017	30 (59)	0 (0)	0 (0)	16 (31)	1 (2)	0 (0)	0 (0)	4 (8)	51
2016	26 (47)	3 (5)	0 (0)	20 (36)	1 (2)	1 (2)	0 (0)	4 (7)	55
2015	27 (54)	1 (2)	0 (0)	18 (36)	1 (2)	0 (0)	0 (0)	3 (6)	50
2014	28 (62)	0 (0)	0 (0)	15 (33)	0 (0)	0 (0)	0 (0)	2 (4)	45
2013	20 (57)	0 (0)	0 (0)	14 (40)	0 (0)	0 (0)	0 (0)	1 (3)	35
2012	28 (72)	0 (0)	0 (0)	9 (23)	0 (0)	0 (0)	0 (0)	2 (5)	39
2011	19 (66)	0 (0)	0 (0)	7 (24)	0 (0)	0 (0)	0 (0)	3 (10)	29
2010	19 (53)	0 (0)	0 (0)	14 (39)	0 (0)	0 (0)	0 (0)	3 (8)	36
2009	22 (56)	0 (0)	0 (0)	14 (36)	1 (3)	0 (0)	0 (0)	2 (5)	39
2008	20 (56)	0 (0)	0 (0)	12 (33)	0 (0)	0 (0)	0 (0)	4 (11)	36
2007	16 (55)	2 (7)	1 (3)	9 (31)	0 (0)	0 (0)	0 (0)	1 (3)	29
2006	25 (64)	0 (0)	0 (0)	8 (21)	0 (0)	0 (0)	0 (0)	6 (15)	39
2005	21 (62)	2 (6)	1 (3)	8 (24)	0 (0)	0 (0)	0 (0)	2 (6)	34
2004	15 (52)	2 (7)	2 (7)	8 (28)	0 (0)	0 (0)	0 (0)	2 (7)	29
2003	19 (61)	0 (0)	1 (3)	5 (16)	0 (0)	0 (0)	0 (0)	6 (19)	31
2002	15 (56)	1 (4)	0 (0)	9 (33)	0 (0)	0 (0)	0 (0)	2 (7)	27
2001	11 (46)	0 (0)	0 (0)	10 (42)	0 (0)	0 (0)	0 (0)	3 (13)	24
2000	18 (62)	0 (0)	0 (0)	8 (28)	0 (0)	0 (0)	0 (0)	3 (10)	29
1999	11 (58)	1 (5)	0 (0)	5 (26)	0 (0)	0 (0)	0 (0)	2 (11)	19
1998	14 (74)	0 (0)	0 (0)	4 (21)	0 (0)	0 (0)	0 (0)	1 (5)	19
1997	11 (69)	0 (0)	0 (0)	5 (31)	0 (0)	0 (0)	0 (0)	0 (0)	16
1996	11 (92)	0 (0)	0 (0)	1 (8)	0 (0)	0 (0)	0 (0)	0 (0)	12
1995	11 (85)	0 (0)	0 (0)	2 (15)	0 (0)	0 (0)	0 (0)	0 (0)	13
1994	10 (67)	0 (0)	0 (0)	5 (33)	0 (0)	0 (0)	0 (0)	0 (0)	15
1993	9 (82)	0 (0)	0 (0)	2 (18)	0 (0)	0 (0)	0 (0)	0 (0)	11
1992	7 (70)	0 (0)	0 (0)	3 (30)	0 (0)	0 (0)	0 (0)	0 (0)	10
1991	7 (88)	0 (0)	0 (0)	1 (13)	0 (0)	0 (0)	0 (0)	0 (0)	8
1990	8 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	8
1989	5 (71)	0 (0)	1 (14)	1 (14)	0 (0)	0 (0)	0 (0)	0 (0)	7
1988	4 (67)	0 (0)	0 (0)	2 (33)	0 (0)	0 (0)	0 (0)	0 (0)	6
1987	2 (67)	0 (0)	0 (0)	1 (33)	0 (0)	0 (0)	0 (0)	0 (0)	3
1986	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
1985	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
1984	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	1
Total	539 (60)	15 (2)	6 (<1)	266 (29)	5 (<1)	1 (<1)	7 (<1)	66 (7)	905

SPK, simultaneous pancreas-kidney; PAK, pancreas after kidney; PTA, pancreas alone

The above table excludes the four transplants performed in Australia outside of Westmead, Monash, or Royal Adelaide in 1988, 1990, 2005, and 2017.

The above table also excludes one combined liver-pancreas transplant performed at Monash in 2016.

Patients transplanted by state

The states of origin of the people receiving pancreas transplants at each transplant unit in Australia over time are shown in Table 2.2.

Table 2.2: Distribution of state of residence of people receiving pancreas transplants over time

	State of residence, n (row %)								
Year	NSW	VIC	QLD	WA	SA	TAS	ACT	NT	Total
Westmead (NSW)									
2019	15 (56)	0 (0)	10 (37)	2 (7)	0 (0)	0 (0)	0 (0)	0 (0)	27
2018	15 (58)	0 (0)	6 (23)	3 (12)	2 (8)	0 (0)	0 (0)	0 (0)	26
2017	14 (47)	0 (0)	11 (37)	2 (7)	1 (3)	0 (0)	2 (7)	0 (0)	30
Monash (VIC)									
2019	0 (0)	7 (70)	0 (0)	0 (0)	1 (10)	2 (20)	0 (0)	0 (0)	10
2018	0 (0)	17 (85)	0 (0)	0 (0)	2 (10)	1 (5)	0 (0)	0 (0)	20
2017	0 (0)	14 (82)	0 (0)	0 (0)	2 (12)	1 (6)	0 (0)	0 (0)	17
Royal Adelaide (SA)									
2019	0 (0)	0 (0)	0 (0)	0 (0)	3 (100)	0 (0)	0 (0)	0 (0)	3
2018	0 (0)	0 (0)	0 (0)	0 (0)	4 (100)	0 (0)	0 (0)	0 (0)	4
2017	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Auckland (NZ)									
2019	-	-	-	-	-	-	-	-	4
2018	-	-	-	-	-	-	-	-	6
2017	-	-	-	-	-	-	-	-	4

Demographics of new pancreas transplant recipients

The characteristics of pancreas transplant recipients in 2019 and in previous years are shown in Table 2.3. The primary diagnosis causing end stage kidney disease of recipients during 2019 and historically was type I diabetes. The number of diabetic recipients with other cause of end stage kidney failure was small. The number of type II diabetics accepted for pancreas transplantation was also small, and none were transplanted in 2019.

Table 2.3: Demographics and characteristics of pancreas transplant recipients

Patients, n (column %)	2019	1984-2018	Total
Age category			
Median (IQR)	39 (35, 44)	39 (33, 44)	39 (33, 44)
0-34	9 (20)	276 (34)	285 (33)
35-44	25 (56)	391 (48)	416 (48)
45-50	9 (20)	140 (17)	149 (17)
50+	1 (2)	59 (7)	60 (7)
Sex			
Female	23 (52)	403 (49)	426 (49)
Male	21 (47)	463 (57)	484 (56)
Cause of end stage kidney disease			
Diabetes type 1	43 (97)	843 (97)	886 (97)
Diabetes type 2	0 (0)	1 (<1)	1 (<1)
Haemolytic uraemic syndrome	0 (0)	1 (<1)	1 (<1)
Interstitial nephritis	0 (0)	1 (<1)	1 (<1)
Wegener's granulomatosis	0 (0)	1 (<1)	1 (<1)
No kidney disease ¹	1 (2)	17 (1)	18 (1)
Not reported	0 (0)	2 (<1)	2 (<1)
Ethnicity²			
Indigenous Australian	0 (0)	2 (<1)	2 (<1)
Maori	3 (6)	5 (<1)	8 (<1)
Pacific islander	1 (2)	9 (1)	10 (1)
White	37 (84)	820 (94)	857 (94)
North Asian	0 (0)	3 (<1)	3 (<1)
South-East Asian	0 (0)	0 (0)	0 (0)
Southern and Central Asian	0 (0)	17 (1)	17 (1)
North African and Middle Eastern	3 (6)	9 (1)	12 (1)
Not reported	0 (0)	1 (<1)	1 (<1)
Blood group			
O	19 (43)	406 (50)	425 (49)
A	20 (45)	339 (41)	359 (42)
B	4 (9)	80 (9)	84 (9)
AB	1 (2)	41 (5)	42 (4)
Total	44	866	910

¹ Ethnicity classified according to the Australian Bureau of Statistics standard classification, 2nd Edition;

<http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/1249.02011>

² Includes 11 pancreas transplants after kidney (PAK) and 6 pancreas transplants alone (PTA)

The type of pancreas transplants and the types of donors for transplants performed in 2019 is presented in Table 2.4, stratified by country and sex.

Table 2.4: Transplant and donor types in 2019 by country and sex¹

	Australia		New Zealand		Overall		Total
	Female	Male	Female	Male	Female	Male	
Pancreas alone	0	2	0	0	0	2	2
<i>DBD</i>	0	1	0	0	0	1	1
<i>DCD</i>	0	1	0	0	0	1	1
SPK	10	21	1	1	11	22	33
<i>DBD</i>	8	18	1	1	9	19	28
<i>DCD</i>	2	3	0	0	2	3	5

DBD, donor after brain death; DCD, donor after circulatory death; SPK, simultaneous pancreas-kidney

¹ Donor sex not reported for 9 transplants

Balance of donor and recipient characteristics in 2019

Cross tabulations of donor and recipient blood group and gender for people transplanted in 2019 are displayed in Table 2.5 and Table 2.6. These distributions remain similar to previous years.

Table 2.5: Cross tabulation of recipient and donor blood groups for 2019

Recipient blood group	Donor blood group ¹ , n (row %)				Total
	O	A	B	AB	
O	17 (100)	0 (0)	0 (0)	0 (0)	17
A	3 (15)	16 (84)	0 (0)	0 (0)	19
B	0 (0)	0 (0)	4 (100)	0 (0)	4
AB	0 (0)	1 (100)	0 (0)	0 (0)	1
Total	20 (48)	17 (41)	4 (9)	0 (0)	41

¹ Donor blood group not reported for 3 transplants

Table 2.6: Cross tabulation of recipient and donor sex for 2019

Recipient sex	Donor sex ¹ , n (row %)		Total
	Female	Male	
Female	6 (40)	9 (60)	15
Male	5 (25)	15 (75)	20
Total	11 (31)	24 (68)	35

McNemar's test for difference p=0.4


¹ Donor sex not reported for 9 transplants

Patient survival

Patient survival is calculated from the date of transplantation until death. Patients still alive at the end of the follow-up period are censored. For people who had more than one transplant, their survival is calculated from the date of their first transplant. For these analyses we had survival data for 889 patients, 21 of whom have received a second pancreas transplant, for a total of 910 pancreas transplants. Note that for the following survival plots survival proportion on the y-axis does not always start at zero; this is to better demonstrate some observed differences.


Figure 2.3 shows overall survival following pancreas transplant. There were 8,572 years of follow-up, and 147 people died in that time. Survival at 1 year was 96.6%, at 5 years 93.3%, at 10 years 84.1% and at 15 years 79.0%.

Figure 2.3: Patient survival following pancreas transplantation in Australia and New Zealand.




Patient survival by era of transplantation is shown in Figure 2.4. Survival has improved over time ($p < 0.001$). Survival at 1 year for people transplanted before 2000 was 92.6%; in recent years this has risen to 96.9%. Survival at 5 years was 88.5% for those transplanted before 2000, where for those transplanted in 2010 or later, 5-year survival was 94.3%.

Figure 2.4: Patient survival by era of transplantation



Patient survival by age at transplantation is shown in Figure 2.5. People that were older at the time of pancreas transplantation had poorer survival than those who were younger ($p=0.03$). Survival at 1 year for recipients aged <35 years was 97.1%, and for those aged 35-44 was 96.7%, whereas for those aged 45-49 was 95.1% and for those 50 or older was 96.6%. Survival at 5 years for those aged <35 years was 92.8%, and for those aged 35-44 was 94.4%, whereas for those aged 45-49 was 91.1% and for those 50 or older was 93.2%. The greater survival for the 50 years and older group may be because these recipients are a more highly selected population.

Figure 2.5: Patient survival by age at transplantation



Pancreas survival

Pancreas transplant survival was calculated from the time of transplant until the time of permanent return to insulin therapy or pancreatectomy. We calculated both pancreas failure including death with a functioning pancreas and pancreas failure censored at death with a functioning transplant. For pancreas transplant survival we included all pancreas transplants undertaken, including those who had received a pancreas transplant twice (21 patients). At the time of this report, we had survival records for 910 pancreas transplants.

Figure 2.6 shows pancreas transplant survival censored at death. Over 7,377 years of follow-up, there were 145 pancreas transplant failures (excluding people who died with a functioning transplant). Overall, 1-year pancreas transplant survival was 90.7%, 5-year survival 86.3%, and 10-year survival 83.0%.

Figure 2.6: Pancreas transplant survival (censored at death)






Figure 2.7 shows pancreas transplant survival including death with a functioning pancreas. Over the same observation time there were 255 recipients who either died or experienced pancreas transplant failure. Survival at 1, 5 and 10 years was 88.6%, 81.6% and 71.9% respectively.

Figure 2.7: Pancreas transplant survival (including death as transplant failure)




Survival of pancreas transplants has changed over time, as shown in Figure 2.8. Survival improved markedly over time ($p=0.001$). For those transplanted prior to 2000, 1-year pancreas transplant survival was 82.3%, and 5-year survival 76.6%. For those transplanted in 2010 or later, 1-year survival was 94.0% and 5-year survival 89.0%.

Figure 2.8: Pancreas transplant survival over time (censored at death)




Pancreas transplant survival by donor BMI is presented in Figure 2.9. Most donors (64%) were either underweight or normal weight (BMI <25). However, 32% were overweight (BMI 25-29) and 4% were obese (BMI 30+). While Figure 2.9 suggests separation of survival curves, there was no statistical association between donor BMI and pancreas survival ($p=0.6$). Pancreas transplant survival at 1 year was 91.5% for transplants where the donor was underweight/normal BMI, 90.0% for transplants where the donor was overweight, and 86.1% where the donor was obese.

Figure 2.9: Pancreas transplant survival by donor BMI (censored at death)



Pancreas transplant survival by donor age is presented in Figure 2.10. The survival curves are poorer for donors aged 35-44 compared with those 45 and older, or younger donors ($p=0.02$). We can only hypothesise that any difference may be due to donors over 45 being a more highly selected group, compared to the donors aged 35-44. Pancreas transplant survival at 1 year was 92.8% for transplants from donors aged 6-24 years, 90.3% for donors aged 25-34 years, 86.2% for donors aged 35-44 years, and 93.9% for donors aged 45+ years.

Figure 2.10: Pancreas transplant survival by donor age (censored at death)



Pancreas transplant survival at 1 year and 5 years post-transplant, censored at death and stratified by country and era of transplantation is presented in Table 2.7.

Table 2.7: Pancreas transplant survival censored at death, by country and era

Year of transplant	Australia					New Zealand				
	N	1-year		5-year		N	1-year		5-year	
		n	%	n	%		n	%	n	%
2011-2016	239	215	91.6%	109	86.5%	15	14	93.3%	7	93.3%
2012-2017	261	236	92.6%	88	87.6%	16	15	93.8%	4	93.8%
2013-2018	274	250	93.7%	60	89.9%	20	19	95.0%	2	95.0%
2014-2019	280	220	94.5%	34	92.3%	23	18	95.7%	1	95.7%

Prevalence of functioning pancreas transplants

We calculated the point prevalence of people living in Australia and New Zealand who were alive with a functioning transplant on 31st December each year for the last five years (Table 2.8). The below numbers exclude people still alive, but whose pancreas transplant has failed. The number of functioning transplants is remaining steady over time, possibly because recipients of early transplants are ageing (with increased deaths and pancreas transplant failures) which is being offset by the increase in new transplants performed.

Table 2.8: People alive with a functioning pancreas transplant in Australia and New Zealand by year and residence, at year's end

State/country of residence	2015	2016	2017	2018	2019
New South Wales	171	168	164	163	162
Victoria	184	184	181	179	177
Queensland	129	126	122	122	122
Western Australia	36	35	32	31	31
South Australia	53	52	52	51	50
Tasmania	27	27	27	27	27
Australian Capital Territory	14	13	12	12	12
Northern Territory	4	4	4	4	4
New Zealand	52	52	52	52	52
Total	670	661	646	641	637

Kidney transplant survival

Kidney transplant survival was calculated for those who received SPK transplants, from the time of transplantation until the time of return to dialysis. We calculated both kidney failure including death with a functioning kidney and kidney failure censored at death with a functioning graft. For kidney transplant survival we included only SPK transplants and excluded PAK transplant recipients. We had survival records for 877 SPK transplants.

Figure 2.11 shows kidney survival censored at death. Over 7,729 years of observation, there were 88 kidney transplant failures (excluding people who died with a functioning kidney transplant). Overall, 1-year kidney transplant survival was 97.1%, 5-year survival 94.3%, and 10-year survival 89.5%.

Figure 2.11: Kidney transplant survival for people receiving SPK transplants (censored at death)






Figure 2.12 shows kidney survival including death with a functioning kidney. Over the same observation time there were 196 recipients who either died with kidney transplant function or experienced kidney transplant failure. Kidney transplant survival at 1, 5 and 10 years was 94.7%, 89.3% and 77.6% respectively.

Figure 2.12: Kidney transplant survival for people receiving SPK transplants (including death as a kidney transplant failure)




Kidney transplant survival improved over time, with longer survival for those transplanted in more recent years ($p < 0.001$). For those transplanted before 2000, kidney transplant survival was 92.3% at 1 year and 88.6% at 5 years but was 98.3% at 1 year and 97.2% at 5 years for those transplanted in 2010 or later (Figure 2.13).

Figure 2.13: Kidney transplant survival for SPK recipients over time (censored at death)



The era effect was even stronger when considering kidney failure including death with kidney function ($p < 0.001$). For those transplanted before 2000, survival was 87.8% at 1 year and 81.0% at 5 years but was 96.2% at 1 year and 93.4% at 5 years for those transplanted in 2010 or later (Figure 2.14).

Figure 2.14: Kidney transplant survival for SPK recipients over time (including death as a kidney transplant failure)



Pancreas transplant operative data

Characteristics of the pancreas transplant operations for 2019, previous years, and overall are shown in Table 2.9 below.

Table 2.9: Descriptive characteristics of pancreas transplant operations

	2019	1984-2018	Total
Pancreas transplant			
Total pancreas transplants	44	866	910
Cold ischaemic time (hours)			
Patients (%)	27 (61)	700 (81)	727 (80)
Mean (SD)	8.5 (2.9)	11.3 (19.6)	11.2 (19.2)
Median (IQR)	8 (6, 10)	10 (8, 12)	10 (8, 12)
Anastomosis time (minutes)			
Patients (%)	8 (18)	687 (79)	695 (76)
Mean (SD)	24.0 (6.0)	29.7 (8.0)	29.7 (8.0)
Median (IQR)	25 (20, 29)	30 (25, 34)	30 (25, 34)
Exocrine drainage			
Enteric, n (%)	44 (100)	629 (73)	673 (74)
Bladder, n (%)	0 (0)	164 (19)	164 (18)
Not reported, n (%)	0 (0)	73 (8)	73 (8)
Kidney transplant			
Total SPK transplants	42	835	877
Cold ischaemic time (hours)			
Patients (%)	25 (57)	675 (78)	700 (77)
Mean (SD)	8.5 (3.1)	11.3 (19.9)	11.2 (19.6)
Median (IQR)	8 (6, 10)	10 (8, 12)	10 (8, 12)
Anastomosis time (minutes)			
Patients (%)	7 (16)	661 (76)	668 (73)
Mean (SD)	24.9 (6.0)	29.8 (8.0)	29.7 (8.0)
Median (IQR)	26 (22, 30)	30 (25, 34)	30 (25, 34)
Kidney donor arteries			
None, n (%)	0 (0)	2 (<1)	2 (<1)
One, n (%)	28 (64)	609 (70)	637 (70)
Two, n (%)	1 (2)	68 (8)	69 (8)
Three, n (%)	0 (0)	4 (<1)	4 (<1)
Not reported, n (%)	13 (30)	152 (18)	165 (18)

SPK, simultaneous pancreas-kidney

To investigate how much the total cold ischaemic time varied dependant on the donor state, and distance travelled to the transplanting centre, Table 2.10 displays a cross tabulation of donor state of origin with transplanting centre.

Table 2.10: Comparison of cold ischaemic time of pancreas transplants by donor state, for Australian pancreas transplants 2019


Donor state	Cold ischaemic time in hours					
	Westmead (NSW)		Monash (VIC)		Royal Adelaide (SA)	
	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
New South Wales	7	7.1 (1.2)	0	-	0	-
Victoria	1	9 (-)	9	8.9 (3.5)	0	-
Queensland	2	9 (1.4)	0	-	0	-
Western Australia	2	8 (4.2)	0	-	2	6.5 (2.1)
South Australia	0	-	1	10 (-)	0	-
Tasmania	0	-	0	-	0	-
Australian Capital Territory	1	5 (-)	0	-	0	-
Northern Territory	0	-	0	-	1	12 (-)
Total	13	7.5 (1.9)	10	10.5 (3.5)	3	8.5 (4.9)

Note: There is a lot of missing data for cold ischaemic times, hence data in this table may not be representative of all pancreas transplants

Surgical technique

Exocrine drainage of the pancreas transplant has changed over time. Enteric drainage of the pancreas was first used in Australia and New Zealand during 2001. Figure 2.15 illustrates the number of transplants by pancreas duct management. Since 2001, most pancreas transplants have used enteric drainage of the pancreas duct.

Figure 2.15: Change in management of exocrine drainage of the pancreas over time



The site of donor vessel anastomoses onto the recipient vessels is dependent on many things, including but not limited to surgeon's preference, surgical ease of access, length and relative calibre of donor vessels. The sites of anastomosis for donor arteries and veins are displayed in Figure 2.16 and Figure 2.17 below.

Figure 2.16: Site of donor artery anastomosis onto recipient vessel





Figure 2.17: Site of donor vein anastomosis onto recipient vessel



The immunological matching of donor-recipient pairs is shown in Table 2.11, and the cytomegalovirus (CMV) and Epstein-Barr virus (EBV) matching is illustrated in Table 2.12.

Table 2.11: Immunological cross-matching of donor recipient pairs

	Donor-recipient pairs, n (column %)	
	<i>Current</i>	<i>Peak</i>
Crossmatch		
T-cell Positive	0 (0)	2 (<1)
B-cell Positive	3 (<1)	4 (<1)
T and B cell Negative	745 (82)	730 (80)
DTT Negative	1 (<1)	1 (<1)
None recorded	0 (0)	2 (<1)
Not reported	161 (18)	171 (19)
Panel Reactive Antibodies (%)		
0-49	132 (15)	130 (14)
50+	1 (<1)	9 (<1)
Not reported	777 (85)	771 (85)

Table 2.12: Infectious disease serology cross-tabulation of donor-recipient pairs

Recipient serology	Donor serology, n (column %)		
	<i>Positive</i>	<i>Negative</i>	<i>Not reported</i>
Cytomegalovirus (CMV)			
Positive	96 (18)	45 (14)	4 (8)
Negative	16 (3)	9 (3)	0 (0)
Not reported	425 (79)	271 (83)	44 (92)
Epstein-Barr virus (EBV)			
Positive	120 (23)	18 (22)	28 (9)
Negative	3 (<1)	0 (0)	1 (<1)
Not reported	408 (77)	65 (78)	267 (90)

Chapter 3: Pancreas donors

Authors: Angela Webster, Paul Robertson, Tia Mark, James Hedley, Patrick Kelly

This chapter gives an overview of donors in 2019 and over time. Donor eligibility criteria guidelines are available in the TSANZ consensus statement

<http://www.tsanz.com.au/organallocationprotocols/> , but briefly require donors to be over 25kg, and up to the age of 45, without known diabetes mellitus or pancreatic trauma, or history of alcoholism or pancreatic trauma. Donation after cardiac death may be considered up to the age of 35. As these are guidelines, there may be occasions when there is minor deviation from these advised criteria.

Donor BMI is perceived as impacting recipient outcomes. Obese donors are more likely to have fatty pancreas, which results in more difficult surgery and increased post –operative complications, and suboptimal insulin secretion. Alcohol consumption is defined by a history of consumption of more than 40g/day. Table 3.1 describes pancreas donor characteristics in Australia and New Zealand to date.

Pancreas donor characteristics

Table 3.1: Demographics and characteristics of pancreas transplant donors

	Donors, n (column %)		
	2019	1984-2018	Total
Total (row %)	44 (100)	866 (100)	910 (100)
Age category			
0-24	13 (30)	412 (48)	425 (47)
25-34	14 (32)	226 (26)	240 (26)
35-44	7 (16)	192 (22)	199 (22)
45+	0 (0)	33 (4)	33 (4)
Not reported	10 (23)	3 (<1)	13 (1)
Sex			
Female	11 (25)	506 (58)	517 (57)
Male	24 (55)	359 (41)	383 (42)
Not reported	9 (20)	1 (<1)	10 (1)
BMI (kg/m2)			
Underweight/Normal (<24.9)	18 (41)	556 (64)	574 (63)
Overweight (25-29.9)	12 (27)	271 (31)	283 (31)
Obese (30+)	0 (0)	36 (4)	36 (4)
Not reported	14 (32)	3 (<1)	17 (2)
Donor type			
Brain death (DBD)	38 (86)	854 (99)	892 (98)
Circulatory death (DCD)	6 (14)	12 (1)	18 (2)
Donor mode of death			
Cerebral hypoxia/ischaemia	14 (32)	101 (12)	115 (13)
Cerebral infarct	0 (0)	17 (2)	17 (2)
Intracranial haemorrhage	7 (16)	231 (27)	238 (26)
Non-neurological condition	0 (0)	194 (22)	194 (21)
Other neurological condition	2 (5)	18 (2)	20 (2)
Traumatic brain injury	11 (25)	302 (35)	313 (34)
Not reported	10 (23)	3 (<1)	13 (1)
Alcohol consumption			
Never	16 (36)	653 (75)	669 (74)
Former	3 (7)	4 (<1)	7 (<1)
Current	11 (25)	49 (6)	60 (7)
Not reported	14 (32)	160 (18)	174 (19)
Smoking history			
Never	14 (32)	519 (60)	533 (59)
Former	3 (7)	34 (4)	37 (4)
Current	14 (32)	208 (24)	222 (24)
Not reported	14 (32)	105 (12)	119 (13)
Donor's blood group			
O	20 (45)	440 (51)	460 (51)
A	17 (39)	321 (37)	338 (37)
B	4 (9)	83 (10)	87 (10)
AB	0 (0)	21 (2)	21 (2)
Not reported	3 (7)	1 (<1)	4 (<1)

	Donors, n (column %)		
	2019	1984-2018	Total
Kidney biopsy			
Performed	15 (34)	654 (76)	669 (74)
Not performed	24 (55)	187 (22)	211 (23)
Not reported	5 (11)	25 (3)	30 (3)
Cytomegalovirus (CMV)			
Positive	26 (59)	511 (59)	537 (59)
Negative	5 (11)	320 (37)	325 (36)
Not reported	13 (30)	35 (4)	48 (5)
Epstein-Barr virus (EBV)			
Positive	24 (55)	507 (59)	531 (58)
Negative	2 (5)	81 (9)	83 (9)
Not reported	18 (41)	278 (32)	296 (33)

DBD, donor after brain death; DCD, donor after circulatory death

The distribution of donor states of origin by transplanting unit for Australian pancreas donors is shown in Table 3.2.

Table 3.2: Distribution of state of residence of pancreas donors in Australia over time, by national pancreas transplant unit

State	Donors, n (column %)					
	2019	2018	2017	2016	2015	2014
Westmead (NSW)						
NSW	14 (52)	13 (50)	14 (47)	10 (34)	15 (54)	10 (36)
VIC	3 (11)	1 (4)	0 (0)	1 (3)	1 (4)	2 (7)
QLD	4 (15)	7 (27)	4 (13)	10 (34)	4 (14)	3 (11)
WA	4 (15)	2 (8)	7 (23)	5 (17)	4 (14)	3 (11)
SA	1 (4)	0 (0)	1 (3)	0 (0)	3 (11)	5 (18)
TAS	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
ACT	1 (4)	3 (12)	3 (10)	3 (10)	1 (4)	5 (18)
NT	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)
Monash (VIC)						
NSW	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	1 (7)
VIC	9 (90)	17 (85)	15 (88)	16 (70)	16 (84)	11 (73)
QLD	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)
WA	0 (0)	1 (5)	1 (6)	3 (13)	0 (0)	1 (7)
SA	1 (10)	1 (5)	0 (0)	2 (9)	3 (16)	0 (0)
TAS	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	2 (13)
ACT	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
NT	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

State	Donors, n (column %)					
	2019	2018	2017	2016	2015	2014
Royal Adelaide (SA)						
NSW	0 (0)	0 (0)	0 -	0 -	0 -	0 -
VIC	0 (0)	0 (0)	0 -	0 -	0 -	0 -
QLD	0 (0)	0 (0)	0 -	0 -	0 -	0 -
WA	0 (0)	0 (0)	0 -	0 -	0 -	0 -
SA	2 (67)	3 (75)	0 -	0 -	0 -	0 -
TAS	0 (0)	0 (0)	0 -	0 -	0 -	0 -
ACT	0 (0)	0 (0)	0 -	0 -	0 -	0 -
NT	1 (33)	1 (25)	0 -	0 -	0 -	0 -

Donor and recipient state/territory

Table 3.3 shows the distribution of donor organs according to state of origin, cross-tabulated with the state of origin of the recipients who received those organs, for 2019, and from inception of the pancreas program. Note, these tables include Australian donors and recipients only.

Table 3.3: Number of pancreas transplants by donor and recipient state of residence in Australia for 2019 and all years

Recipient state	Donor state (number of transplants)									Total
	NSW	VIC	QLD	WA	SA	TAS	ACT	NT	Not reported	
2019 only	14	12	4	4	4	0	1	1	0	40
NSW	7	2	2	3	1	0	0	0	0	15
VIC	0	6	0	0	1	0	0	0	0	7
QLD	6	0	2	1	0	0	1	0	0	10
WA	1	1	0	0	0	0	0	0	0	2
SA	0	1	0	0	2	0	0	1	0	4
TAS	0	2	0	0	0	0	0	0	0	2
ACT	0	0	0	0	0	0	0	0	0	0
NT	0	0	0	0	0	0	0	0	0	0
All years (1984-2019)	318	248	77	58	74	23	38	3	3	842
NSW	151	11	28	19	22	4	18	0	0	253
VIC	22	190	1	5	7	16	2	0	3	246
QLD	74	9	29	16	23	0	11	1	0	163
WA	21	5	12	10	5	1	2	0	0	56
SA	17	20	3	5	13	1	5	2	0	66
TAS	16	12	1	0	1	1	0	0	0	31
ACT	16	1	3	1	2	0	0	0	0	23
NT	1	0	0	2	1	0	0	0	0	4

Chapter 4: Islet cell transplants

Authors: Patricia Anderson, Natasha Rogers, Henry Pleass, James Hedley, Angela Webster, on behalf of the Australian Islet Consortium

Islet transplants are a treatment for type 1 diabetics who have hypoglycaemic unawareness and/or severe metabolic instability, are sensitive to insulin, but who have minimal or no kidney impairment. Whole donor pancreas organs are processed aiming to produce a concentrate of islet cells >4000 islet equivalent numbers (IEQ)/kg in a volume of <9ml. Islet transplant recipients generally require more than one islet transplant to become insulin independent.

Data for islet transplant donors and recipients in Australia are still sparse. The islet transplant program started in 2002. There are two islet isolation facilities in Australia; St Vincent's Hospital Melbourne in Victoria, and Westmead hospital in New South Wales. There are three active islet transplant centres; the National Pancreas Transplant Unit at Westmead Hospital, St Vincent's Hospital Melbourne, and the Royal Adelaide Hospital. There is no islet transplant program in New Zealand. This chapter contains information about allogenic islet transplants (i.e. islets from a deceased donor), whereas Chapter 5 contains information about autologous islet transplants (i.e. islets isolated from the recipient's own pancreas).

In this year's report we have added as much data as we have available on the islet program in Australia to date, and expanded description to capture the waiting list for islet transplants, donor and recipient characteristics. We have only reported islet donors and procedures that were intended to be used for an islet transplantation, and not islet isolation procedures that were undertaken only for research purposes. Some donor isolations intended for transplantation did not proceed to transplantation, generally because the pancreas processing failed set release criteria, with the major reason being insufficient concentration of islet cells.

The islet program waiting list is intentionally not long. Table 4.2 shows the number of patients referred for an islet transplant in 2019 by state of residence and the transplant centre they were referred to. Table 4.2 shows the number of patients accepted onto an islet waiting list during 2019, while Table 4.3 shows the islet waiting list activity over time.

Table 4.1: Referrals for allogenic islet transplant during 2019 by state of residence and transplant centre

State of residence	Westmead	St. Vincent's	Royal Adelaide	Total
New South Wales	0	0	0	0
Victoria	0	19	0	19
Queensland	2	1	0	3
Western Australia	0	0	0	0
South Australia	0	0	0	0
Tasmania	0	0	0	0
Australian Capital Territory	0	0	0	0
Northern Territory	0	0	0	0

Table 4.2: Patients accepted onto a waiting list for an allogenic islet transplant during 2019 by state of residence and transplant centre

State of residence	Westmead	St. Vincent's	Royal Adelaide	Total
New South Wales	0	0	0	0
Victoria	0	0	0	0
Queensland	1	1	0	2
Western Australia	0	0	0	0
South Australia	0	0	0	0
Tasmania	0	0	0	0
Australian Capital Territory	0	0	0	0
Northern Territory	0	0	0	0

Table 4.3: Islet waiting list status over time; Westmead Hospital (NSW), St Vincent's Hospital (VIC), and Royal Adelaide Hospital (SA)

	Patients (n)				
	2019	2018	2017	2016	2015
Waiting list activity					
Active list at beginning of year	12	14	8	3	6
Added to active list during the year	1	14	17	16	17
<i>First transplant</i>	-	10	11	9	13
<i>Second transplant</i>	-	6	4	8	7
<i>Third transplant</i>	-	0	3	0	1
Removed from active list during year	16	10	10	10	19
<i>First transplant</i>	-	8	5	4	16
<i>Second transplant</i>	-	6	4	8	7
<i>Third transplant</i>	-	0	3	0	1
Death while active on list	0	0	0	0	0
Death within 12 months of removal from list	0	0	0	0	0
Active waiting list at the end of year	-3	16	14	8	3
Transplants to waiting list					
Recipients	6	10	10	10	19
Transplants	9	14	12	12	24
Under consideration but not active on list	4	10	1	1	1
Referred but declined for islet transplantation	12	0	0	0	0

Note: Includes simultaneous islet kidney transplants. Some patients with multiple transplants in the same year were added and removed multiple times

Islet isolations

Sometimes when pancreas donations are processed for islet transplantation, the resulting islets do not meet transplant release criteria. The decision to proceed with transplantation is made once release testing is complete and the quality and quantity of islet cells is known. Islet isolation procedures follow good manufacturing procedure (GMP) guidelines as set out by the Australian Therapeutic Goods Administration (TGA). Isolations occur at one of two dedicated isolation facilities at Westmead (Sydney) and St. Vincent's Institute (SVI, Melbourne), both associated with their respective local hospitals Westmead and St. Vincent's Hospital. Occasionally preparations are sent between Melbourne and Sydney, however Royal Adelaide Hospital has no islet isolation facility and is dependent on islets from either Westmead or St. Vincent's Institute, with the latter being its main provider of islets. A summary of islet cell isolation activity by centre and year is presented in Table 4.4.

Table 4.4: Summary of allogenic islet cell isolation activity, for all centres in Australia

Activity	2019	2002-2018	Total
Westmead (NSW)			
Pancreata donations discarded before isolation	0	9	9
Islet isolations			
<i>Islet isolations used for transplant</i>	9	54	63
<i>Islet isolations discarded</i>	0	181	181
Islet recipients	6	28-33	34-39
St. Vincent's (VIC)			
Pancreata donations discarded before isolation	0	59	59
Islet isolations			
<i>Islet isolations used for transplant</i>	7	52	59
<i>Islet isolations discarded</i>	8	154	162
Islet recipients	6	24-30	24-30

Some recipients with multiple transplants have received islets from both Westmead and St. Vincent's.

The donor characteristics of islet cell donor isolations are presented in Table 4.5 (Westmead Hospital), Table 4.6 (St. Vincent's Hospital), and Table 4.7 (Westmead and St Vincent's hospitals combined). Donor characteristics are influenced in part by the Australian donor pancreas allocation policy which allocates pancreata for both pancreatic islet isolation and for whole pancreas transplantation. This policy is available at <https://www.tsanz.com.au/organallocationguidelines/index.asp>

Table 4.5: Donor characteristics from allogenic islet isolations performed in Westmead Hospital (NSW)

	Donors (n)		
	2019	2002 - 2018	Total
Total	15	261	276
Age			
Mean (SD)	43.9 (10.4)	45.4 (12.7)	45.3 (12.6)
0-24	1	23	24
25-34	1	33	34
35-44	6	48	54
45+	7	156	163
Not reported	0	1	1
Sex			
Female	4	105	109
Male	11	153	164
BMI kg/m²			
Mean (SD)	31.0 (3.6)	28.8 (6.5)	28.9 (6.4)
Underweight (<18.5)	0	3	3
Normal weight (18.5-24)	0	85	85
Overweight (25-29)	7	85	92
Obese (30+)	8	87	95
Not reported	0	1	1
State of residence			
New South Wales	6	121	127
Victoria	4	47	51
Queensland	3	36	39
Western Australia	0	34	34
South Australia	0	13	13
Tasmania	1	5	6
Australian Capital Territory	1	3	4
Northern Territory	0	0	0
Not reported	0	2	2
Donor type			
Brain dead (DBD)	13	242	255
Circulatory death (DCD)	1	8	9
Not reported	1	0	0
Donor mode of death			
Cerebral hypoxia/ischaemia	2	26	28
Cerebral infarct	0	13	13
Intracranial haemorrhage	9	121	130
Non-neurological condition	0	27	27
Other neurological condition	0	3	3
Traumatic brain injury	4	23	27
Not reported	0	40	40
Days ventilated prior to donation			
Mean (SD)	3.6 (3.0)	2.9 (2.5)	2.9 (2.5)

	Donors (n)		
	2019	2002 - 2018	Total
Alcohol consumption			
Never	5	17	22
Former	0	2	2
Current	9	133	142
Not reported	0	109	109
Smoking history			
Never	3	51	54
Former	1	3	4
Current	10	136	146
Not reported	0	71	71
Cultural and ethnic group			
Indigenous Australian or Torres Strait Islander	0	1	1
Maori or Pacific Islander	0	0	0
White	15	212	227
North East Asian (Chinese)	0	1	1
South East Asian	0	4	4
South and Central Asian (Indian)	0	1	1
Middle Eastern or North African	0	0	0
Other	0	2	2
Not reported	0	40	40
Blood group			
O	7	130	137
A	7	105	112
B	1	17	18
AB	0	8	8
Not reported	0	1	1
CMV serology			
Negative	4	116	120
Positive	11	85	96
Not reported	0	20	20

Table 4.6: Donor characteristics for allogenic islet isolations performed in St Vincent's Hospital (VIC)

	Donors (n)		
	2019	2002 - 2018	Total
Total	15	157	172
Age			
Mean (SD)	53.7 (10.2)	48.2 (13.1)	48.7 (12.9)
0-24	0	10	10
25-34	1	15	16
35-44	2	29	31
45+	12	103	115
Sex			
Female	7	78	85
Male	8	79	87
BMI kg/m²			
Mean (SD)	29.2 (4.1)	28.6 (6.3)	28.7 (6.1)
Underweight (<18.5)	0	0	0
Normal weight (18.5-24)	3	51	54
Overweight (25-29)	6	53	59
Obese (30+)	6	53	59
State of residence			
New South Wales	3	13	16
Victoria	6	81	84
Queensland	1	1	2
Western Australia	0	5	5
South Australia	4	39	41
Tasmania	1	10	11
Australian Capital Territory	0	2	2
Northern Territory	0	5	5
Not reported	0	1	1
Donor type			
Brain dead (DBD)	15	148	163
Circulatory death (DCD)	0	9	9
Donor mode of death			
Cerebral hypoxia/ischaemia	4	32	36
Cerebral infarct	5	11	16
Intracranial haemorrhage	2	59	61
Non-neurological condition	0	7	7
Other neurological condition	0	9	9
Traumatic brain injury	4	14	18
Not reported	0	25	25
Days ventilated prior to donation			
Mean (SD)	3.3 (1.5)	3.0 (1.9)	3.0 (1.9)

		Donors (n)	
	2019	2002 - 2018	Total
Alcohol consumption			
Never	2	26	28
Former	0	3	3
Current	13	91	104
Not reported	0	37	37
Smoking history			
Never	4	49	53
Former	4	18	22
Current	7	52	59
Not reported	0	38	38
Cultural and ethnic group			
Indigenous Australian or Torres Strait Islander	0	0	0
Maori or Pacific Islander	0	1	1
White	15	65	79
North East Asian (Chinese)	0	0	0
South East Asian	0	1	1
South and Central Asian (Indian)	0	0	0
Middle Eastern or North African	0	0	0
Other	0	1	1
Not reported	0	89	89
Blood group			
O	8	92	100
A	3	45	48
B	3	9	12
AB	1	4	5
Not reported	0	7	7
CMV serology			
Negative	4	46	50
Positive	11	55	66
Not reported	0	56	56

Table 4.7: Donor characteristics for allogenic islet isolations (all centres)

	Donors (n)		
	2019	2002 - 2018	Total
Total	30	418	448
Age			
Mean (SD)	48.8 (11.3)	46.5 (12.9)	46.7 (12.8)
0-24	1	33	34
25-34	2	48	50
35-44	8	77	85
45+	19	259	278
Not reported	0	1	1
Sex			
Female	12	184	196
Male	11	153	164
BMI kg/m²			
Mean (SD)	30.1 (3.9)	28.7 (6.4)	28.8 (6.3)
Underweight (<18.5)	3	54	57
Normal weight (18.5-24)	6	138	144
Overweight (25-29)	13	138	151
Obese (30+)	8	87	95
Not reported	3	14	17
State of residence			
New South Wales	7	122	129
Victoria	4	52	56
Queensland	7	75	82
Western Australia	1	44	45
South Australia	0	15	15
Tasmania	1	10	11
Australian Capital Territory	1	4	5
Northern Territory	0	0	0
Not reported	15	150	165
Donor type			
Brain dead (DBD)	13	242	255
Circulatory death (DCD)	5	40	45
Not reported	6	11	17
Donor mode of death			
Cerebral hypoxia/ischaemia	2	33	35
Cerebral infarct	0	22	22
Intracranial haemorrhage	13	135	148
Non-neurological condition	0	52	52
Other neurological condition	0	3	3
Traumatic brain injury	4	23	27
Not reported	0	40	40
Days ventilated prior to donation			
Mean (SD)	3.5 (2.3)	2.9 (2.3)	2.9 (2.3)

Alcohol consumption			
Never	5	54	59
Former	0	2	2
Current	13	182	195
Not reported	4	127	131
Smoking history			
Never	3	89	92
Former	1	3	4
Current	10	136	146
Not reported	0	72	72
Cultural and ethnic group			
Indigenous Australian or Torres Strait Islander	0	1	1
Maori or Pacific Islander	0	1	1
White	15	212	227
North East Asian (Chinese)	0	1	1
South East Asian	0	5	5
South and Central Asian (Indian)	0	90	90
Middle Eastern or North African	0	0	0
Other	8	94	102
Not reported	3	85	88
Blood group			
O	8	134	142
A	7	112	119
B	1	17	18
AB	4	54	58
Not reported	11	56	67
CMV serology			
Negative	4	116	120
Positive	11	85	96
Not reported	0	20	20

Donors who provided pancreata that resulted in islet isolations that proceeded to transplantation are summarised in Table 4.8.

Table 4.8: Donor characteristics for allogenic islet isolations which resulted in transplantation in 2019


	Donors (n)		
	Westmead	St Vincent's	Total
Total	9	7	16
Age			
Mean (SD)	39.0 (9.2)	50.9 (12.3)	44.2 (12.0)
0-24	1	0	1
25-34	1	1	2
35-44	4	1	5
45+	3	5	8
Sex			
Female	1	3	4
Male	8	4	12
BMI kg/m²			
Mean (SD)	30.9 (3.6)	30.3 (5.3)	30.6 (4.3)
Underweight (<18.5)	0	0	0
Normal weight (18.5-24)	0	2	2
Overweight (25-29)	4	1	5
Obese (30+)	5	4	9
State of residence			
New South Wales	5	2	7
Victoria	2	3	5
Queensland	1	0	1
Western Australia	0	0	0
South Australia	0	2	2
Tasmania	1	0	1
Australian Capital Territory	0	0	0
Northern Territory	0	0	0
Donor type			
Brain dead (DBD)	8	7	15
Circulatory death (DCD)	1	0	1
Donor mode of death			
Cerebral hypoxia/ischaemia	1	0	1
Cerebral infarct	0	3	3
Intracranial haemorrhage	5	0	5
Non-neurological condition	0	0	0
Other neurological condition	0	0	0
Traumatic brain injury	3	4	7
Days ventilated prior to donation			
Mean (SD)	3.6 (2.9)	3.0 (1.2)	3.3 (2.3)

	Donors (n)		
	<i>Westmead</i>	<i>St Vincent's</i>	<i>Total</i>
Alcohol consumption			
Never	5	1	6
Former	0	0	0
Current	4	6	10
Smoking history			
Never	2	4	6
Former	1	2	3
Current	6	1	7
Cultural and ethnic group			
Indigenous Australian or Torres Strait Islander	0	0	0
Maori or Pacific Islander	0	0	0
White	9	7	16
North East Asian (Chinese)	0	0	0
South East Asian	0	0	0
South and Central Asian (Indian)	0	0	0
Middle Eastern or North African	0	0	0
Other	0	0	0
Blood group			
O	4	5	9
A	4	1	5
B	1	0	1
AB	0	1	1
CMV serology			
Negative	2	1	3
Positive	7	6	13

Islet transplant recipients

Figure 4.1 illustrates the number of islet cell transplants in Australia between 2002 and 2019. The transplants were performed in Westmead (73), St Vincent's (30), and Royal Adelaide (18) Hospitals. In 2019, 5 transplants were performed at Westmead, 5 at St Vincent's and 2 at the Royal Adelaide.

Figure 4.1: Allogenic islet transplant activity 2002-2018, by transplanting centre



The characteristics of donor and recipient matches according to blood group are presented in Table 4.9, Table 4.10, and Table 4.11.

Table 4.9: Cross tabulation of recipient and donor blood groups, 2002-2019, from allogenic islet transplants undertaken in Westmead Hospital (NSW)

Recipient blood group	Donor blood group					Total
	<i>O</i>	<i>A</i>	<i>B</i>	<i>AB</i>	<i>Not reported</i>	
<i>O</i>	4	0	0	0	19	23
<i>A</i>	0	2	0	0	39	41
<i>B</i>	0	0	0	0	4	4
<i>AB</i>	0	3	1	0	5	9
Total	4	5	1	0	67	77

Recipients received more than 1 transplant therefore recipients may be duplicated in numbers

Table 4.10: Cross tabulation of recipient and donor blood groups, 2002-2019, from allogenic islet transplants undertaken in St Vincent's hospital (VIC)

Recipient blood group	Donor blood group					Total
	<i>O</i>	<i>A</i>	<i>B</i>	<i>AB</i>	<i>Not reported</i>	
<i>O</i>	10	0	0	0	1	11
<i>A</i>	3	10	0	0	0	13
<i>B</i>	4	0	2	0	1	7
<i>AB</i>	1	1	0	2	0	4
Total	18	11	2	2	2	35

Recipients received more than 1 transplant therefore recipients may be duplicated in numbers

Table 4.11: Cross tabulation of recipient and donor blood groups, 2002-2019, from allogenic islet transplants undertaken in Royal Adelaide Hospital (SA)

Recipient blood group	Donor blood group					Total
	<i>O</i>	<i>A</i>	<i>B</i>	<i>AB</i>	<i>Not reported</i>	
<i>O</i>	9	0	0	0	1	10
<i>A</i>	2	4	0	0	2	8
<i>B</i>	0	0	1	0	1	2
<i>AB</i>	0	0	0	0	0	0
Total	11	4	1	0	4	20

Recipients received more than 1 transplant therefore recipients may be duplicated in numbers

The characteristics of donor and recipient matches according to sex and blood group distributions for all centres are presented in Table 4.12 and Table 4.13.

Table 4.12: Cross tabulation of recipient and donor sex, 2002-2019

Recipient sex	Donor sex			Total
	Female	Male	Not reported	
Female	23	24	42	89
Male	3	10	30	43
Total	26	34	72	132

Recipients could receive more than one transplant and therefore may be duplicated in numbers

Table 4.13: Cross tabulation of recipient and donor blood groups, 2002-2019, for allogenic islet transplants undertaken in Australia

Recipient blood group	Donor blood group					Total
	O	A	B	AB	Not reported	
O	23	0	0	0	21	44
A	5	16	0	0	41	62
B	4	0	3	0	6	13
AB	1	4	1	2	5	13
Total	33	20	4	2	73	132

Recipients could receive more than one transplant and therefore may be duplicated in numbers

State of residence of recipients receiving an islet transplant in 2019, by the order of their transplant is presented in Table 4.14.

Table 4.14: Allogenic islet transplant recipients by state of residence and number of transplants received (all centres, 2019)

Recipient state of residence	1st	2nd	3rd	Total
New South Wales	3	1	1	5
Victoria	1	3	1	5
Queensland	0	0	0	0
Western Australia	0	0	0	0
South Australia	0	0	0	0
Tasmania	0	0	0	0
Australian Capital Territory	0	0	0	0
Northern Territory	0	0	0	0
Total	4	4	2	10

The states of residence of donors and recipients for each transplantation are shown in Table 4.15 and Table 4.16, stratified by year of transplant.

Table 4.15: Cross tabulation of allogenic islet donor and recipient state of residence in 2019

Recipient state of residence	Donor state of residence									Total
	NSW	VIC	QLD	SA	WA	TAS	ACT	NT	Not reported	
NSW	3	1	0	0	0	1	0	0	0	5
VIC	1	1	0	0	0	0	0	1	0	3
QLD	0	2	0	0	0	0	0	0	0	2
SA	0	0	0	0	0	0	0	0	0	0
WA	0	0	0	0	0	0	0	0	0	0
TAS	0	0	0	0	0	0	0	0	0	0
ACT	0	0	0	0	0	0	0	0	0	0
NT	0	0	0	0	0	0	0	0	0	0
Total	4	4	0	0	0	1	0	1	0	10

Recipients could receive more than one transplant and therefore may be duplicated in numbers

Table 4.16: Cross tabulation of allogenic islet donor and recipient state of residence 2002-2018

Recipient state of residence	Donor state of residence								Not reported	Total
	NSW	VIC	QLD	WA	SA	TAS	ACT	NT		
NSW	3	2	0	0	0	1	0	0	56	62
VIC	0	18	0	1	5	3	0	1	2	30
QLD	0	0	0	0	0	0	0	0	2	2
WA	0	0	0	0	0	0	0	0	8	8
SA	2	7	0	0	5	2	1	0	3	20
TAS	0	0	0	0	0	0	0	0	0	0
ACT	0	0	0	0	0	0	0	0	1	1
NT	0	0	0	0	0	0	0	0	0	0
Total	5	27	0	1	10	6	1	1	72	123

Recipients could receive more than one transplant and therefore may be duplicated in numbers

Characteristics of Islet recipients over time are shown in Table 4.17.


Table 4.17: Characteristics of allogenic islet cell transplant recipients in Australia by year of first transplant

	Patients (n)		
	2019	2002-2018	Total
Total	7	58	65
Age			
Mean (SD)	56.5 (11.9)	47.2 (11.5)	48.2 (11.8)
0-24	0	2	2
25-34	1	5	6
35-44	0	15	15
45+	6	36	42
Sex			
Female	5	39	44
Male	2	19	21
State of residence			
New South Wales	3	26	29
Victoria	3	15	18
Queensland	1	2	3
Western Australia	0	4	4
South Australia	0	10	10
Tasmania	0	0	0
Australian Capital Territory	0	1	1
Northern Territory	0	0	0
Blood group			
O	3	21	24
A	1	26	27
B	1	7	8
AB	2	4	6
Number of transplants per recipient			
1	1	15	16
2	4	26	30
3	2	17	19
Wait time from listing to first transplant			
0-1 years	1	16	17
1-2 years	3	3	6
2+ years	3	2	5
Not reported	0	37	37
Insulin independent post-transplant			
Yes	5	21	26
No	2	37	39


Insulin independence defined as being free from insulin use for 14 or more consecutive days

The time from activation on the waiting list to first islet transplant for 2002-2019 is presented in Figure 4.2. Data were available for 10 patients added to the waiting list before 31st December 2019, of whom 7 have received at least one transplant during this period. The median time to first transplant was 2.2 years (IQR 1.4 – 12.6).

Figure 4.2: Time from activation on a waiting list to first allogenic islet transplant




The time from first to second islet transplant for 2002-2019 is presented in Figure 4.3. Median time from first to second islet transplant was 0.8 years (IQR 0.8 – not yet reached).

Figure 4.3: Time from first to second allogenic islet transplant

This figure includes some patients who do not require a second transplant, and hence will never receive one


The time from second to third islet transplant for 2002-2019 is presented in Figure 4.4. The median time from second transplant to third transplant has not yet been reached.

Figure 4.4: Time from second to third allogenic islet transplant

This figure includes some patients who do not require a third transplant, and hence will never receive one

Insulin independence is defined as a person being free from insulin use for at least 14 days. There are 5 patients who have achieved insulin independence; 1 patient before their first transplant, 1 patient after their first transplant, and 3 patients after their third transplant. The duration of insulin independence from the time insulin was first ceased for 2002-2019 is presented in Figure 4.5.

Figure 4.5: Duration of insulin independence from time first ceased



Chapter 5: Islet auto-transplants

Authors: Toby Coates, Henry Pleass, James Hedley, Angela Webster, on behalf of the Australian Islet Consortium

Total Pancreatectomy and Autologous Islet Transplantation (auto-islet transplant, TP-IAT) is an important and growing program, targeting a small number of people with rare diseases. This process is a treatment for people who have certain, often inherited (Hereditary Pancreatitis, HP), diseases of the pancreas which cause them severe and chronic pain. The most common genetic causes of hereditary pancreatitis are genetic abnormalities in the PRSS-1 gene, SPINK-1 gene, and other genes in the trypsinogen pathway. Chronic pancreatitis causes prolonged inflammation in the pancreas, and this in turn causes progressive scarring. It may also cause disturbed digestion and impaired growth in children, and as the disease progresses people may become diabetic. Often, people with this problem require very high doses of strong pain killers, and have reduced quality of life. Autologous islet transplantation is a process by which a person is their own donor. An individual's own pancreas is removed, the islet cells isolated, and then transplanted back into the patient. The main reason to do this is to reduce the chronic pain people experience and to improve their quality of life. In cases where chronic pancreatitis is due to HP there is a significant risk of development of adenocarcinoma of the pancreas by middle age. In these cases, TP-IAT may also be regarded as preventing pancreatic adenocarcinoma. Up to 40% of people undergoing an auto-islet transplant are insulin independent after the procedure, and another 30% show partial independence, the rest are insulin dependent. Auto-islet transplantation occurs in two Australian centres only; Westmead in NSW and The Royal Adelaide in South Australia. Since Adelaide does not have an Islet Isolation facility, the pancreas is sent to St. Vincent's institute Isolation facility and the islets are immediately returned for transplant in Adelaide, with a turn-around time of 5-6 hours.

Waiting list and isolation activity

Since auto-islet transplants do not require a donor, there is no waiting list for auto-islet transplant. However, not everyone referred for consideration of auto-islet transplant is suitable for the procedure. People with very long-standing chronic pancreatitis may have such a scarred pancreas that their islet cells have been destroyed. These people may benefit more from alternative treatments. For other people there may be reasons to wait a period of time before undergoing an auto-transplant. The number of patients waiting for an auto-islet transplant at each islet centre at the end of 2019 is presented in Table 5.1.

Table 5.1: Patients waiting for an auto-islet transplant at the end of 2019, by transplant centre

	Patients (n)
Westmead	
<i>Under consideration</i>	2
<i>Accepted on the waiting list</i>	0
Royal Adelaide	
<i>Under consideration</i>	0
<i>Accepted on the waiting list</i>	0

For auto-islet transplants occurring in Adelaide, the pancreatectomy happens in Adelaide, but the isolation procedure is done at St Vincent's hospital in Melbourne, after which the islet isolate is returned to Adelaide for the transplant to occur. The number of transplants performed in Australia by year across all islet centres is presented in Table 5.2.

Table 5.2: Auto-islet isolation/transplant activity by year

Year	Westmead	Royal Adelaide ¹	Total
2019	1	3	4
2018	1	2	2
2017	0	3	3
2016	1	1	1
2015	1	1	1
2014	0	0	0
2013	0	0	0
2012	0	0	0
2011	0	0	0
2010	1	0	0
Total	4	7	7

¹ Isolations performed at St. Vincent's Hospital

Patient characteristics

The characteristics of auto-islet transplant recipients by year of transplantation are presented in Table 5.3.

Table 5.3: Characteristics of auto-islet transplant recipients by year of transplant

Characteristic, mean (SD)	2019	2010-2018	Total
Patients, n	4	11	15
Age, years	22.5 (12.5)	23.8 (14.2)	23.5 (13.3)
Patient weight, kg	54.8 (20.3)	55.6 (21.0)	55.4 (20.1)
Pancreas weight, g	59.0 (11.8)	39.2 (22.7)	44.5 (21.9)
Islet equivalent (IEQ) total ('000)	339 (148.7)	183 (67.1)	225 (114.5)
Islet equivalent (IEQ) per kilogram ('000)	7 (3.6)	4.0 (2.3)	4.8 (2.9)

Appendices

Previous ANZIPTR Reports

An abridged version of the ANZIPTR annual report for 2018 pancreas chapters (chapters 1-3) was published in Transplantation Direct, and can be viewed here:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233667/>

The ANZIPTR annual report for 2018 pancreas chapters should be cited as follows:

AC Webster et al., Transplantation Direct. 2018; 4(10): e390

An abridged version of the ANZIPTR annual report for 2018 islets chapters (chapters 4-5) was also published in Transplantation Direct, and can be viewed here:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415971/>

The ANZIPTR annual report for 2018 islet chapters should be cited as follows:

AC Webster et al., Transplantation Direct. 2019; 5(2): e421

Other abstracts and publications

Data from ANZIPTR was used in the following abstracts that were presented at conferences in 2018:

Conference: Transplant Society of Australia and New Zealand (TSANZ) Annual Scientific Meeting

Location: Melbourne, Australia

Date: 29th April – 1st May 2018

Authors: Webster, A; Hedley, J; Kelly, P

Title: Post-Transplant Survival in Type 1 Diabetics in Australia and New Zealand

Conference: The Transplantation Society (TTS) Annual Scientific Meeting

Location: Madrid, Spain

Date: 30th June – 5th July 2018

Authors: Hedley, J; Kelly, P; Webster, A

Title: Post-Transplant Survival in Type 1 Diabetics in Australia and New Zealand

Conference: Australian and New Zealand Society of Nephrology (ANZSN) Annual Scientific Meeting

Location: Sydney, Australia

Date: 8th - 12th September 2018

Authors: Hedley, J; Kelly, P; Webster, A

Title: Kidney graft survival and patient survival in type 1 diabetics after kidney transplant alone compared to simultaneous pancreas-kidney transplant